Clinical Trial: Diagnosing Adult Growth Hormone Deficiency
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Diagnosis of Adult Growth Hormone Deficiency With Growth Hormone Releasing Hormone Plus Arginine Stimulation Test
Brief Summary: The purpose of this study was to validate the growth hormone releasing hormone (GHRH) plus arginine (GHRH+arg) stimulation test and it´s cut-off limits for diagnosis of adult growth hormone deficiency using the growth hormone (GH) Immulite 2000 Xpi assay calibrated against the IS 98/574 from the World Health Organization. A specific aim was to study the effect of gender and age on the peak GH response in the GHRH+arg test
Detailed Summary:
Adult growth hormone deficiency (AGHD) is a clinical entity including increased abdominal fat mass, decreased muscle mass, low bone density and adverse effects on quality of life and cardiovascular morbidity. These signs are nonspecific, and accurate diagnosis with laboratory tests in needed.
The GHRH+arg test is used to diagnose AGHD, but the cut-off values vary based on controls used. At moment consensus cut-off criteria are BMI specific, but gender and age may also affect the GH response in the GHRH+arg.
Sponsor: Helsinki University Central Hospital
Current Primary Outcome: Peak serum GH (ug/l) by Immulite 2000 Xpi [ Time Frame: one year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Serum insulin like growth hormone 1 (IGF-1) concentration [ Time Frame: one year ]
- Basal serum GH (ug/l) by Immulite 2000 Xpi [ Time Frame: one year ]
Original Secondary Outcome: Same as current
Information By: Helsinki University Central Hospital
Dates:
Date Received: January 6, 2017
Date Started: May 2001
Date Completion:
Last Updated: January 11, 2017
Last Verified: January 2017
